UroGen (URGN) 2025 Earnings: What Investors Should Know
As UroGen prepares to report 2025 results, investors weigh Jelmyto sales, pipeline progress, and balance-sheet health...
This tag page gathers 4 Pharmaceuticals articles covering stock moves, earnings previews, and dip-buys to help you evaluate pharma equities and manage risk.
30 articlesAs UroGen prepares to report 2025 results, investors weigh Jelmyto sales, pipeline progress, and balance-sheet health...
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
When a blue-chip pharma stock falls 25%, many investors wonder if it's time to buy. This guide breaks down how to ass...
As Bausch Health prepares its Q4 2025 results, investors want clarity on margins, debt, and the pipeline. This guide ...
If you’re seeking a single, enduring reason to own Lilly stock, this article lays it out. You’ll learn how a durable ...
SPDR S&P Pharmaceuticals ETF has delivered a standout one-year run, yet the longer five-year view casts a shadow. The...